Celldex Therapeutics, Inc.

NASDAQ:CLDX

Biotechnology

Healthcare
$27.96 +0.47%

+$0.16 today

Market cap
$2.20B
Beta
0.93
P/E (TTM)
-7.8
EPS (TTM)
-$4.26
52W Low $19.52High $35.79

Volume 0.75M

Average 0.94M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$210.94M

FY 2025 · Annual

Investing Cash Flow

$209.07M

FY 2025 · Annual

Financing Cash Flow

$2.39M

FY 2025 · Annual

-99.5% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(70.51M)(112.33M)(141.43M)(157.86M)(258.76M)
Depreciation & Amortization3.07M2.9M3.01M3.18M3.38M
Deferred Income Tax(227K)0000
Stock-Based Compensation8.95M023.89M34.24M36.22M
Change in Working Capital(1.05M)(3.9M)13.46M(21.6M)14.06M
Accounts Receivables1.57M(175K)(2.28M)1.93M(1.32M)
Inventory00000
Accounts Payables3.65M3.12M9.38M11.63M11.03M
Other Working Capital(6.28M)(6.85M)6.36M(35.16M)4.34M
Other Non-Cash Items(1.14M)9.6M(6.22M)(15.73M)(5.84M)
Operating Cash Flow(60.91M)(103.73M)(107.29M)(157.78M)(210.95M)
Capital Expenditures(1.25M)(1.83M)(1.82M)(1.92M)(2.71M)
Acquisitions (Net)27K69K000
Purchases of Investments(389.88M)(188.97M)(424.56M)(789.92M)(384.5M)
Sales of Investments174.95M280.67M320.6M501.71M596.29M
Other Investing Activities00000
Investing Cash Flow(216.16M)89.94M(105.78M)(290.13M)209.07M
Debt Repayment00000
Common Stock Issued269.89M4.08M216.22M432.3M2.39M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.48M02.24M9.15M0
Financing Cash Flow272.37M4.08M218.46M441.45M2.39M
Effect of Forex Changes00000
Net Change in Cash(4.69M)(9.71M)5.39M(6.46M)515K
Free Cash Flow(62.16M)(105.56M)(109.11M)(159.7M)(213.66M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$258.8M
+ D&A$3.4M
+ Stock-Based Comp$36.2M
+ Deferred Tax$0
+ Working Capital$14.1M
- Other Non-Cash-$5.8M
= Operating Cash Flow-$210.9M
- Capex-$2.7M
= Free Cash Flow-$213.7M

Analysis

FY2025 free cash flow is -$213.7M. FCF conversion is 82.6% of net income. Operating cash flow was -$210.9M, with capex of -$2.7M. The largest bridge item is Stock-Based Comp at $36.2M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
S-3ASRS-3ASR filingNov 5, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 5, 2026
SC 13G/ASC 13G/A filingOct 7, 2026
8-KCurrent reportSep 22, 2026

Does CLDX generate free cash flow?

Celldex Therapeutics, Inc. (CLDX) generated -$213.66M of free cash flow in fiscal 2025.

How much operating cash flow does CLDX produce?

Operating cash flow was -$210.94M, before capital expenditures of $2.71M.